Table 3 Participant characteristics
Study name, funder(s) | Number of males: females | Ethnicity | Employment | Age | Disease duration / treatment initiation | Participant experience of remote consultations |
|---|---|---|---|---|---|---|
Improving Fracture Prevention Study (iFraP), NIHR, ROS, Haywood Foundation | 1:5 | White | 1 working 1 retired 3 unknown | Mean 68 (range 60–71) | Diagnosed at their recent FLS appointment | Participants had received telephone consultations either pre or early pandemic in both FLS and primary care about osteoporosis |
Blast Off Study (Bisphosphonate aLternAtive regimenS for the prevenTion of Osteoporotic Fragility Fractures), NIHR | 0:15 | Data not collected | 4 working (2 employed; 2 doing voluntary work) 5 retired 6 unknown | Mean 67 (range 58–75) | Initiated bisphosphonate treatment (oral or IV) between 1997 and 2020 | Telephone consultations with primary care clinicians and specialists about osteoporosis |
Experiences of patients with RA, during the coronavirus pandemic (ERA), Haywood Foundation, NIHR | 6:9 | White | 4 working 1 not working 10 retired | Mean 64 (range 46–78) | Disease duration mean 22.2 years (range 1.5–46 years) | Telephone consultations with specialists in secondary care and primary care about RA |